Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
ERK
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN16763 | XMD8-92 | 1234480-50-2 | XMD8-92 is an inhibitor of ERK5BMK1 The Kd values for BMK1 DCAMKL2 PLK4 and TNK1 are 80 nM 190 nM 600 nM and 890 nM respectively |
| CSN17855 | XMD17-109 | 1435488-37-1 | XMD17-109 is a specific ERK-5 inhibitor with an EC50 42 M in HEK293 cells |
| CSN18540 | VX-11e | 896720-20-0 | VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK (Extracellular Signal-Regulated Kinase) and is antitumor agent. |
| CSN15784 | Ulixertinib | 869886-67-9 | Ulixertinib is a potent and reversible ERK1ERK2 inhibitor with IC50 of 0.3 nM for ERK2. |
| CSN23392 | Ulixertinib HCl | 1956366-10-1 | Ulixertinib HCl the salt of ulixertinib is a reversible inhibitor of ERK1ERK2 It can inhibit cell proliferation |
| CSN13154 | Tauroursodeoxycholate Sodium | 35807-85-3 | Tauroursodeoxycholate sodium can suppress ERK via PKC-mediated MKP-1 induction thus inhibiting neointimal hyperplasia of smooth muscle cells |
| CSN13643 | SCH772984 | 942183-80-4 | SCH772984 is a specific inhibitor of ERK12 with IC50 of 4 nM and 1 nM respectively |
| CSN17141 | Pluripotin | 839707-37-8 | Pluripotin is a dual inhibitor of extracellular signal-regulated kinase 1 ERK1 MAPK3 and RasGAP It maintains embryonic stem cell ESC self-renewal |
| CSN21082 | MK-8353 | 1184173-73-6 | MK-8353 also known as SCH900353 is a potent and orally active ERK12 inhibitor and anticancer drug candidate currently being developed by Schering-Plough MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models |
| CSN20623 | LY3214996 | 1951483-29-6 | LY3214996 can inhibit ERK1 and ERK2 with IC50s of 5 nM |
| CSN22441 | KO-947 | 1695533-89-1 | KO-947 is a potent and selective inhibitor of ERK12 kinases with potential clinical utility in MAPK pathway dysregulated tumors |
| CSN16271 | GDC-0994 | 1453848-26-4 | GDC-0994 is a selective inhibitor of ERK1/2 with IC50 value of 6.1 nM and 3.1 nM. |
| CSN19017 | GDC-0994 HCl | 2070009-58-2 | GDC-0994 hydrochloride is highly selective for ERK1 and ERK2 with biochemical potency of 11 nM and 03 nM respectively |
| CSN13064 | FR 180204 | 865362-74-9 | FR 180204 is a potent and selective ATP-competitive inhibitor of ERK1 and ERK2 with Ki value of 031 M and 014 M respectively and has IC50 values of 051 and 033 M in enzymatic assays against ERK1 and ERK2 respectively |
| CSN17601 | ERK5-IN-1 | 1234479-76-5 | ERK5-IN-1 exhibits potent inhibition of ERK5 with cellular EC50 values of 019 M and enzymatic IC50 values of 0087 M and of LRRK2G2019S with enzymatic IC50 values of 0026M |
| CSN18045 | DEL-22379 | 181223-80-3 | DEL-22379 inhibits ERK dimerization with IC50 of 05 M |
| CSN13519 | Corynoxeine | 630-94-4 | Corynoxeine is a potent ERK12 inhibitor of key PDGF-BB-induced VSMC proliferation and is a useful and prospective compound in the prevention and treatment for vascular diseases |
| CSN22365 | CC-90003 | 1621999-82-3 | CC-90003 is an irreversible inhibitor of ERK 12 with antitumor activity |
| CSN21094 | AZD0364 | 2097416-76-5 | AZD0364 is an ERK1 andor ERK2 kinase for the treatment of cancer |
| CSN19016 | APS-2-79 | 2002381-25-9 | APS-2-79 is an antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site |
| CSN21221 | AG-126 | 118409-62-4 | AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 M. |
| CSN20372 | ADA-07 | N/A | ADA-07 a T-LAK cell-originated protein kinase TOPK inhibitor is a promising chemopreventive or potential therapeutic agent against SUV-induced skin carcinogenesis that acts by specifically targeting TOPK |
| CSN22695 | AX 15836 | 2035509-96-5 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
